Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk (Q46318630)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk |
scientific article |
Statements
1 reference
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk (English)
1 reference
Fairooz Kabbinavar
1 reference
Cornelia Irl
1 reference
Alfredo Zurlo
1 reference
Herbert Hurwitz
1 reference
14 October 2008
1 reference
1 reference
75
1 reference
3-4
1 reference
215-223
1 reference
Identifiers
1 reference